Alkermes plc.
At today's price, Alkermes plc. (ALKS) is priced for today's economics sustained for ~8.3 years. boothcheck doesn't publish a fair value or a price target; it shows what the price assumes, so you can judge whether that bar is too high. Built from SEC EDGAR filings.
• Alkermes runs a profitable commercial psychiatry and addiction franchise (VIVITROL, ARISTADA, LYBALVI) whose cash funds a single high-stakes bet: a wholly owned orexin program led by alixorexton for sleep disorders, with the February 2026 Avadel acquisition adding the marketed narcolepsy drug LUMRYZ on top. • The whole price rests on that pipeline, because none of the standard valuation lenses reaches today's $44.90: on assets, earnings power, peer multiples, and even forward growth the shares
Is ALKS overvalued? See what's priced in →
374 institutional managers reported holding ALKS in 13F filings for the quarter ended 2026-03-31. 63 opened new positions that quarter. Held by BlackRock, Vanguard Group, State Street, among others. On the short side, 18.0M shares were sold short as of the 2026-06-15 count, about 11% of shares outstanding (9.5 days of typical volume to cover).
Quarterly 13F filings arrive up to 45 days after quarter end, so the picture is never current (filed through 2026-05-29). Nothing here is investment advice.
ALKS's share count grew 3.3% over the past five years even with $227.98M spent on repurchases. It pays no dividend. Cash returned over the past three years: $227.98M in repurchases.
Share counts are split-adjusted; repurchase totals are gross of share issuance. Nothing here is investment advice.
No open-market insider buys on file at ALKS over the trailing three years. Absence is a fact about the company, not a signal. 15 officers and directors are on file.
Code P open-market purchases from SEC Form 4 filings, non-derivative, excluding scheduled 10b5-1 plans. Nothing here is investment advice.
ALKS's recent reports: the day-one move, then what the following quarter actually did.
| report | day one | next quarter |
|---|---|---|
| 2023-07-27 | -1.8% | -7.0% |
| 2023-10-26 | -2.5% | +12.9% |
| 2024-02-22 | +15.0% | -15.5% |
| 2024-05-02 | -2.8% | +1.6% |
Day-one is the close-to-close move around the filing. Nothing here is investment advice.
ALKS's latest 8-K filings: 2026-07-08 (items 1.02); 2026-06-15 (items 7.01, 8.01, 9.01); 2026-05-20 (items 5.02, 5.07, 9.01); 2026-05-12 (items 7.01, 8.01, 9.01); 2026-05-05 (items 2.02, 9.01).
Item codes are the SEC's own classification of what each report discloses. Nothing here is investment advice.
Last analyzed: June 27, 2026
Each week boothcheck ranks the stocks whose prices are betting on the most. Read the most stretched bets archive →
boothcheck is also on Android. Get the app on Google Play →
For informational and research purposes only. Not investment advice. Not a recommendation to buy, sell, or hold any security. boothcheck is not a registered investment adviser. Past performance does not guarantee future results.